Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:CMPS NASDAQ:IMCR NASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.69+0.6%$15.23$4.64▼$18.60$1.52B-0.111.23 million shs611,999 shsCMPSCompass Pathways$11.80+8.6%$7.45$2.25▼$12.01$1.61B2.393.60 million shs3.59 million shsIMCRImmunocore$29.92+1.3%$30.21$27.56▼$40.71$1.51B0.74410,177 shs163,929 shsIRDOpus Genetics$4.38-1.5%$4.97$0.90▼$5.81$352.87M0.62909,735 shs365,370 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+6.83%-6.65%-22.54%-2.92%+146.56%CMPSCompass Pathways+7.94%-0.82%+14.90%+31.60%+135.28%IMCRImmunocore+2.11%+2.04%-6.10%-10.94%-8.80%IRDOpus Genetics+4.15%-11.73%-19.86%+24.37%+346.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.69+0.6%$15.23$4.64▼$18.60$1.52B-0.111.23 million shs611,999 shsCMPSCompass Pathways$11.80+8.6%$7.45$2.25▼$12.01$1.61B2.393.60 million shs3.59 million shsIMCRImmunocore$29.92+1.3%$30.21$27.56▼$40.71$1.51B0.74410,177 shs163,929 shsIRDOpus Genetics$4.38-1.5%$4.97$0.90▼$5.81$352.87M0.62909,735 shs365,370 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+6.83%-6.65%-22.54%-2.92%+146.56%CMPSCompass Pathways+7.94%-0.82%+14.90%+31.60%+135.28%IMCRImmunocore+2.11%+2.04%-6.10%-10.94%-8.80%IRDOpus Genetics+4.15%-11.73%-19.86%+24.37%+346.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.77Moderate Buy$23.0067.99% UpsideCMPSCompass Pathways 2.92Moderate Buy$20.5874.38% UpsideIMCRImmunocore 2.60Moderate Buy$57.7593.03% UpsideIRDOpus Genetics 2.80Moderate Buy$10.18132.73% UpsideCurrent Analyst Ratings BreakdownLatest IRD, IMCR, AMLX, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026IRDOpus Genetics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.005/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.005/14/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $17.005/14/2026CMPSCompass Pathways Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $22.005/13/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.005/13/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $11.005/12/2026IRDOpus Genetics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/7/2026CMPSCompass Pathways UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.005/7/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Strong-Buy5/5/2026CMPSCompass Pathways Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M17.42N/AN/A$2.46 per share5.57CMPSCompass PathwaysN/AN/AN/AN/A$2.42 per shareN/AIMCRImmunocore$412.81M3.67N/AN/A$7.77 per share3.85IRDOpus Genetics$14.20M25.08N/AN/A($0.56) per share-7.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)CMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A271.98N/A-6.68%-7.07%-2.55%8/6/2026 (Estimated)IRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%5/21/2026 (Estimated)Latest IRD, IMCR, AMLX, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IRDOpus Genetics-$0.16-$0.19-$0.03N/A$3.14 million$3.87 million5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/A3/3/2026Q4 2025AMLXAmylyx Pharmaceuticals-$0.31-$0.30+$0.01-$0.30($0.05) millionN/A2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ACMPSCompass PathwaysN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85CMPSCompass Pathways0.153.323.32IMCRImmunocore1.004.184.15IRDOpus GeneticsN/A7.137.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%CMPSCompass Pathways46.19%IMCRImmunocore84.50%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%CMPSCompass Pathways2.82%IMCRImmunocore10.10%IRDOpus Genetics11.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million97.51 millionOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableIMCRImmunocore32050.70 million45.58 millionOptionableIRDOpus Genetics1481.40 million71.87 millionN/AIRD, IMCR, AMLX, and CMPS HeadlinesRecent News About These CompaniesOpus Genetics (NASDAQ:IRD) Director Sells $7,395,000.00 in StockMay 21 at 7:16 AM | insidertrades.comLifesci Capital Predicts Lower Earnings for Opus GeneticsMay 18 at 1:23 AM | marketbeat.comOpus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street ZenMay 16, 2026 | marketbeat.comHC Wainwright Lifts Earnings Estimates for Opus GeneticsMay 15, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Opus Genetics (IRD)May 15, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (IRD), MaxCyte (MXCT) and Solid Biosciences (SLDB)May 14, 2026 | theglobeandmail.comOpus Genetics (NASDAQ:IRD) Stock Rating Lowered by Zacks ResearchMay 14, 2026 | marketbeat.comOpus Genetics (NASDAQ:IRD) Price Target Lowered to $11.00 at Citizens JmpMay 14, 2026 | americanbankingnews.comOpus Genetics (IRD) Projected to Post Earnings on ThursdayMay 14, 2026 | americanbankingnews.comOpus Genetics (IRD) Projected to Post Quarterly Earnings on ThursdayMay 14, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), Opus Genetics (IRD)May 13, 2026 | theglobeandmail.comOpus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare ConferenceMay 13, 2026 | globenewswire.comOpus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2026 | zacks.comOpus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate UpdateMay 12, 2026 | globenewswire.comOpus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal DiseasesMay 7, 2026 | globenewswire.comOpus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy StudyMay 7, 2026 | globenewswire.comHere is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ StocksMay 5, 2026 | insidermonkey.comOpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramMay 4, 2026 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 4, 2026 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)May 2, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC)May 2, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAST SpaceMobile Drops 15% After Blue Origin Satellite MishapBy Jessica Mitacek | April 22, 2026AST SpaceMobile Gets FCC Green Light for Direct-to-Device Service After Launch SetbackBy Jessica Mitacek | April 28, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?By Jessica Mitacek | May 12, 2026Why AST SpaceMobile Is the Bigger Winner of the AT&T, T-Mobile, and Verizon Joint VentureBy Jessica Mitacek | May 20, 2026IRD, IMCR, AMLX, and CMPS Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$13.69 +0.08 (+0.60%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Compass Pathways NASDAQ:CMPS$11.80 +0.93 (+8.59%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Immunocore NASDAQ:IMCR$29.92 +0.38 (+1.28%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Opus Genetics NASDAQ:IRD$4.38 -0.07 (-1.46%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Corpay’s Quiet Strength Is Winning Wall Street Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
